WO1999025826A1 - Method and kit for determining severe inflammatory reactions to mosquito bites - Google Patents
Method and kit for determining severe inflammatory reactions to mosquito bites Download PDFInfo
- Publication number
- WO1999025826A1 WO1999025826A1 PCT/IB1998/001961 IB9801961W WO9925826A1 WO 1999025826 A1 WO1999025826 A1 WO 1999025826A1 IB 9801961 W IB9801961 W IB 9801961W WO 9925826 A1 WO9925826 A1 WO 9925826A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mosquito
- antigens
- ige
- species
- allergens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Mosquito bites are a global problem not only because they facilitate transmission of potentially fatal diseases such as malaria and yellow fever, but also because they cause local skin reactions and, rarely, systemic reactions including urticaria, angioedema, and even anaphylactic shock [Frazier, 1973; McCormack et al . , 1995] .
- Skin reactions to mosquito bites are caused by the proteins in the mosquito saliva that enter the skin when mosquitoes take a blood meal
- Mosquito saliva proteins elicit both IgE-mediated immediate hypersensitivity and lymphocyte-mediated delayed hypersensitivity [Oka 1989; Peng et al . , 1996] .
- Mosquito salivary proteins are also involved with many aspects of the process of hematophagy which provide new perspectives for evaluating the transmission dynamics of pathogens [James, 1994] .
- Mosquito saliva contains a complex of proteins. Protein visualization techniques using gel electrophoresis and silver staining have revealed as many as 20 pep ides in adult mosquito Aedes aegypti saliva [Racioppi and Spielman, 1987] , which include ⁇ - amylase, anticoagulants, anti-TNF, apyrase, esterase, D7, ⁇ -glucosidase, and sialokinins [James, 1994] .
- Immunotherapy is successful in the treatment of mosquito allergy [Frazier, 1973; Gluck and Pacin, 1968; McCormack, 1995; Tager et al, 1969; Benaim-Pinto and Fassrainer, 1990] , correlating with the observation that natural desensitization eventually occurs during long-term exposure to the bites [Mellanby, 1946; McKiel and West, 1961; Peng, et al, 1994, 1996] .
- This therapy is neither well studied nor widely used at least in part because commercially available mosquito extracts have never been standardized and contain many non- saliva proteins which may cause sub optimal efficacy and side effects.
- mosquito saliva protein Commercial extracts of mosquito saliva protein are available. Commercial mosquito extracts contain multiple proteins and antigens since they are whole body extracts (Example 1) . Many of the antigens in these extracts are unrelated to the allergens in mosquito saliva. The antibodies exhibited in patients which are directed against these non-saliva antigens in the commercial extracts may have been induced by inhalation of insect particles or by being bitten by other insects whose antigens cross-reacted with mosquito body components leading to the formation of IgE and IgG antibodies against mosquito body antigens. Commercial mosquito extracts should be standardized given their extreme heterogeneity (Example 1) and purer mosquito extracts should be used in the diagnosis and immunotherapy of mosquito allergy.
- recombinant proteins are needed that are not species- shared and which can be used as an allergen in a standardized extract for skin testing and immunotherapy (desensitization) .
- recombinant proteins that are species-specific are also needed so that appropriate combinations of allergens can be made that are patient-specific.
- a recombinant mosquito salivary allergen for use in skin tests, immunoassays and immunotherapy for allergic reactions to mosquito bites.
- the recombinant allergen is produced by a cDNA encoding an IgE-binding protein or fragment thereof or analogue thereof which is found in mosquito saliva.
- the recombinant allergen is rAed a 1, a 68 kDa recombinant allergen, or rAed a 2, a 37 kDa recombinant allergen or rAed a 3, a 30 kDa recombinant allergen.
- the recombinant allergen may share common allergenicity among at least two species of mosquitos or may be species-specific .
- the present invention also provides a method of skin testing and undertaking immunotherapy utilizing the recombinant salivary allergen and a kit for practicing the method of the invention.
- the recombinant allergens are selected to share common allergenicity among the mosquito species for which testing or treatment is required.
- a combination of allergens with common specificities among species is used so as to effectively represent the mosquito species distribution of a wide geographic area for which testing and/or immunotherapy is needed.
- the present invention also provides an immunoassay for measurement of mosquito salivary allergen-specific IgE and IgG using recombinant mosquito salivary allergen as the substrate to which the allergen- specific IgE and IgG binds.
- the present invention also provides a kit for the immunoassay including the appropriate recombinant allergen, antibody directed to the allergen and may also contain reference sera.
- the present invention further provides antibodies directed against the recombinant salivary allergens, wherein the recombinant allergen is produced by a cDNA encoding an IgE-binding protein or fragment thereof or analogue thereof which is found in mosquito saliva.
- the antibody is directed against rAed a— 1, a 68 kDa recombinant allergen, or rAed a 2, a 37 kDa recombinant allergen or rAed a 3, a 30 kDa recombinant allergen.
- the antibody may be polyclonal or monoclonal.
- the antibodies are used for immunoassays, purification and antigen standardization.
- Figure 1 shows the results of using nitrocellulose filters to characterize cDNA coding protein using specific mouse and human antibodies to the protein
- Figure 2 shows results for mean mosquito-specific IgE levels of three species and the subjects with or without immediate skin reaction to mosquito bites
- Figure 3 shows the IgE (left) and IgG (right) responses to the antigens of Ae . vexans in three subjects with severe skin reactions to the bites (strip number 1-3) and two subjects without skin reactions to the bites (strips number 4 and 5) ;
- Figure 4 shows a comparison of IgE and IgG responses in three subjects
- Figure 5 shows the results of skin epicutaneous tests
- Figure 6 shows the results of testing of nine subjects with positive rAed a 1 reactions
- Figure 7 shows Western blot analysis showing inhibition of binding by addition of mosquito head and thorax extract in a dose-dependent manner
- Figure 8 shows Aed a 2 to be a species-shared allergen being present in saliva or salivary glad extracts
- Figure 9 shows individual IgE responses to allergens evaluated in twelve mosquito-allergic subjects living in Canada, USA and China as well as five subjects who were not allergic to mosquito bites, immunoblotting being performed using two rabbit antibodies specific to recombinant mosquito salivary proteins; and Figure 10 is an immunoblot using rabbit anti-Aed a 1 and Aed a 2 antibodies respectively.
- the present invention provides recombinant mosquito salivary allergens for use in skin tests, immunoassays and immunotherapy.
- the recombinant allergen is identified and produced by a cDNA encoding an IgE-binding protein or fragment thereof or analogue thereof which is found in mosquito saliva as is shown in the Examples herein.
- the allergen is generally a protein or protein fragment or analogue thereof found in the saliva of mosquitos as described herein above.
- the allergen elicits an IgE response and may also elicit an IgG response.
- the fragment contains some or all of the epitopes on the whole allergen. It elicits an IgE response and may also elicit an IgG response.
- the recombinant allergen expresses the same epitopes, either sequence based or conformational , as the native allergen and shares the same antigenic functions as the native allergen.
- the antigenic functions essentially mean the possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against a naturally occurring salivary protein. Further, the recombinant antigen must also have the same biologic activity, that is it must elicit an immune response in vivo .
- analogue as used herein is defined as a variant (alternatively the terms alteration, amino acid sequence alteration, amino acid sequence variant can be used) with some differences in their amino acid sequences as compared to the native sequence of salivary proteins, but functionally equivalent.
- the analogue will be generally at least 70% homologous over any portion that is functionally relevant for eliciting an immune response.
- the homology will be at least 80% and can approach 95% homology to the mosquito salivary protein sequence. The homology will extend over a region of at least nine contiguous amino acids.
- amino acid sequence of an analog may differ from that of the native protein when at least one residue is deleted, inserted or substituted, but the protein retains its antigenic competence and biological activity in vivo in relation to eliciting an immune response . Differences in glycosylation can provide analogues.
- Functionally equivalent refers to the biological property of the molecule and in this context means an in vivo eliciting of an immune response by a naturally occurring (native) salivary proteins.
- the antigenic functions essentially mean the possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against a naturally occurring salivary protein and eliciting skin reactions as do the native salivary allergens.
- Biologically active in vivo activi ty means that the analogues share an antigenic function and elicit an immune response in vivo .
- any expression system may be used as is known in the art that will provide recombinant allergens or allergen fragments that express the eliciting epitopes and have activity in vivo .
- the allergen is produced in a baculovirus expression vector system.
- recombinant allergens rAed a 1, a 68 kDa recombinant allergen, and/or rAed a 2, a 37 kDa recombinant allergen and/or rAed a 3 SEQ ID No:l
- the allergens are named using the rules as set forth in Larson and Lowenstein [1996] .
- the recombinant allergens can be selected such that they share common allergenicity among at least two species of mosquitos as shown in the Examples .
- the allergen is species specific.
- the allergens used for skin testing are selected on the basis of the mosquito species distribution in the geographic area in which the patient to be tested is exposed or will be exposed. It is contemplated by the present invention that in one embodiment patients moving into new geographic areas or planning to vacation in a new geographic area will be skin tested to determine their sensitivity to the predominant mosquito species population of that area and can then be desensitized as described herein below.
- the allergens may be cross-reactive across several species or may be species-specific.
- the skin testing will utilize the recombinant allergens that effectively represent the mosquito species distribution for the geographic area in which the patient is exposed or will be exposed.
- each recombinant allergen used in skin testing will be determined using in vivo and/or in vi tro standardization techniques.
- the standardization techniques have been described in detail previously [Ipsen et al . 1993] and are summarized herein below.
- Each recombinant allergen extract will be standardized against a standard reference to assure lot-to-lot consistency and relative potency of allergenic recombinant extracts.
- the response to the recombinant mosquito allergens can be determined by an immunoassay as is known in the art and described herein below.
- an ELISA for IgE is preferred but Western
- the present invention also provides a kit including the appropriate recombinant allergen, antibody directed to the allergen and may contain reference sera for the practice of the immunoassay.
- the present invention also provides an allergy immunotherapy medicament which contains the recombinant mosquito allergens for use in immunotherapy (desensitization) as described herein below.
- the recombinant allergens are suspended in pharmaceutically acceptable carriers, diluents, adjuvants and/or vehicles as is known in the art of immunotherapy.
- These pharmaceutically acceptable carriers and the like are selected such that they do not react with the active ingredients of the invention and that the allergens retain their immunologically eliciting conformation and biological activity.
- an alternative term for the immunotherapy medicament is "extract" which is generally used to indicate allergens (immunogens) that have been isolated or prepared from a native or natural source and not produced recombinantly.
- An example of an extract would be mosquito whole body preparations.
- the allergy immunotherapy medicament of the present invention can be referred to as a "recombinant extract” .
- the allergy immunotherapy medicament will contain at least one recombinant mosquito allergen.
- the recombinant mosquito allergens are selected on the basis of the skin test results.
- the starting dose of the allergen can be determined by skin test endpoint-titration using a dose that is equal to
- the medicament will contain a combination of recombinant allergens that effectively represent the mosquito species distribution for the geographic area to which the patient is allergic and for which they need desensitization. —
- the present invention provides a kit for skin testing for allergy to mosquito bites and a kit for providing immunotherapy including recombinant mosquito salivary allergens .
- the kit includes recombinant allergens that are selected to share common allergenicity among the mosquito species common to the geographic area for which testing or immunotherapy is required.
- the kit may also include species-specific recombinant allergens for each mosquito species common to the geographic area for which testing and/or immunotherapy is required.
- the kit includes recombinant allergens rAed al , a 68 kDa recombinant allergen, rAed a2 , a 37 kDa recombinant allergen and rAed a3 , a 30 kDa recombinant allergen.
- skin tests have been used to provide helpful confirmatory evidence for diagnosis of specific allergy. Skin tests include epicutaneous and intradermal tests . Detailed techniques have been previously described [Bousquet and Michel 1993] . Briefly, in the epicutaneous tests, drops of recombinant allergen extracts are placed approximately 2 cm apart on the volar surface of the forearm.
- a starting dose will contain 0.5 allergy units/ml or can be chosen by skin test end-point titration using a dose that is equal to 0.1 ml of the end-point dilution that initiate skin reaction. When the highest tolerated dose is reached, this dose is used to maintain allergen-specific immunity, that is, injected every 2 - 4 weeks for a period of time, as determined by clinical history and monitored immunologic tests.
- Diagnosis of mosquito allergy can be also made by measurement of serum recombinant allergen-specific IgE and IgG antibodies using immunoassays.
- ELISAs are the preferred immunoassays employed to assess the amount of IgE and IgG in a specimen.
- ELISA assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays. Where appropriate, other immunoassays, such as radioimmunoassays (RIA) can be used as are known to those in the art. Available immunoassays are extensively described in the patent and scientific literature.
- any expression system as is known in the art that will provide recombinant allergens or allergen fragments that express the eliciting epitopes and have activity in vivo can be used in the practice of the present invention.
- the baculovirus insect cell expression system which performs many of the post-translational modifications found in mammalian cells, is an excellent system for the production of large amounts of biologically active proteins (see generally O'Reilly et al, 1994.
- Baculovirus Expression Vectors A Laboratory Manual. Oxford University Press
- the efficiency of expression of baculovirus system differs from gene to gene by approximately 1000-fold.
- this system provides for glycosylation such that proper carbohydrate expression is provided which plays a role in the immunological response and in vivo activity.
- Vectors can be constructed containing the cDNA of the present invention, by those skilled in the art, and should contain all expression elements necessary to achieve the desired transcription of the sequences in the selected expression system. Other beneficial characteristics can also be contained within the vectors such as mechanisms for recovery of the nucleic acids in a different form.
- the vectors can also contain elements for use in either procaryotic or eucaryotic host systems. One of ordinary skill in the art will know which host systems are compatible with a particular vector.
- the vectors can be introduced into cells or tissues by any one of a variety of known methods within the art (calcium phosphate transfection; electroporation; lipofection; protoplast fusion; polybrene transfection) .
- the host cell can be any eucaryotic and procaryotic cells, which can be transformed with the vector and which will support the production of the allergen with proper glycosylation and conformation.
- pBlueBacHis vectors are designed for efficient expression and purification of recombinant proteins [Chen et al, 1993; Reddy et al, 1994; Rotrosen et al, 1993; O'Reilly et al , 1994; Matsuura et al . , 1987; Rupp et al . , 1995; Chalkley et al , 1994] and have been used by applicants. Since the variety of expression vector may also play a role in the expression levels of baculovirus system, expression vectors are selected for each recombinant allergen as is known in the art such that the yield of allergen is maximized.
- Expressed recombinant allergens in the cell culture media will be purified according to the physio- biochemical characteristics of each recombinant allergen as is known in the art. For example, histidine tagging [Xu et al . , 1996] for purification of recombinant proteins by immobilized metal affinity chromatography can be used for a number of proteins both in prokaryotic [Dudler et al., 1992.] and eukaryotic [Janssen et al . , 1995; Reddy et al, 1994] expression systems. Other purification systems as are known in the art can be used including affinity chromatography utilizing the monoclonal antibodies to recombinant allergens of the present invention.
- the present invention provides antibodies directed against the recombinant salivary allergens. These antibodies can be used in immunoassays and for — purification and standardization of allergens. Applicants are producing rnAb directed against recombinant allergens in BALB/c mice.
- Antibodies may be either monoclonal or polyclonal and are raised against the immunogen.
- the antibodies may be prepared against the immunogen or part of the immunogen for example a synthetic peptide based on the sequence, or prepared recombinantly by cloning techniques or the natural gene product and/or portions thereof may be isolated and used as the immunogen.
- Such immunogens can be used to produce antibodies by standard antibody production technology well known to those skilled in the art as described generally in Harlow and Lane, Antibodies: A Labora tory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988 and
- Antibody fragments may also be prepared from the antibodies and include Fab, F(ab') 2 , and Fv by methods known to those skilled in the art.
- polyclonal antibodies For producing polyclonal antibodies a host, such as a rabbit or goat, is immunized with the immunogen, generally with an adjuvant and, if necessary, coupled to a carrier; antibodies to the protein are collected from the sera. Further, the polyclonal antibody can be absorbed such that it is monospecific . That is, the sera can be absorbed against related immunogens so that no cross-reactive antibodies remain in the sera rendering it monospecific .
- the technique involves hyperimmunization of an appropriate donor with the immunogen or immunogen fragment, generally from a mouse, and isolation of splenic antibody producing cells.
- These cells are fused to a cell having immortality, such as a myeloma cell, to provide a fused cell hybrid which has immortality and secretes the required antibody.
- the cells are then cultured, in bulk, and the monoclonal antibodies harvested from the culture media for use .
- RNAs from antibody producing B- lymphocytes of animals, or hybridoma are reverse- transcribed to obtain complimentary DNAs (cDNAs) .
- Antibody cDNA which can be full or partial length, is amplified and cloned into a phage or a plasmid.
- the cDNA can be a partial length of heavy and light chain cDNA, separated or connected by a linker.
- the antibody, or antibody fragment is expressed using a suitable expression system to obtain recombinant antibody.
- Antibody cDNA can also be obtained by screening pertinent expression libraries.
- the antibody or antibody fragment can be bound to a solid support substrate or conjugated with a detectable moiety or be both bound and conjugated as is well known in the art.
- a detectable moiety for a general discussion of conjugation of fluorescent or enzymatic moieties see Johnstone & Thorpe, Immunochemistry in Practice,
- the detectable moieties contemplated with the present invention can include, but are not limited to, fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, ⁇ -galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, 1 C and iodination.
- fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, ⁇ -galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, 1 C and iodination.
- a mimetope can be used as the antigenic source. That is a molecule having an epitope the same or similar to the antigenic determinant (epitopes) of interest may be used as the source of the eliciting antigen.
- Skeeter Syndrome should be considered in any patient with cellulitis (a localized area of erythema edema, induration, pain and/or itch) at the site of a mosquito bite and negative cultures.
- Appropriate antibiotic treatment should be continued until a bacterial etiology for the inflammation has been ruled out with certainty; then, topical and/or oral glucocorticoids and an H 1 -antagonist can be substituted.
- the antigens in the kit of the present invention are found in the saliva of the mosquitoes Aedes vexans and Aedes aegypti , and are cross-reactive with other mosquito species. They have been characterized in our laboratory as follows: Antigens :
- Antibodies There are more than 12 antigens in the saliva of Aedes vexans . Their molecular weight ranges between 17.5 and 75 kDa. There are more than eight antigens in the saliva of Aedes aegypti . Their molecular weight ranges between 18.5 and 68 kDa. Antibodies :
- the Aedes vexans or Aedes aegypti salivary antigens are used in the ELISA immunoassays for measurement of mosquito saliva-specific IgE, IgG, and IgG4 antibodies, as known in the art. These assays are applicable to patients presenting with rashes and other symptoms after mosquito bites, especially those with erythema, edema, and induration, pain or itch at the site(s) of mosquito bite(s), with or without fever. Such patients are at risk for severe localized inflammatory reactions and systemic reactions to mosquito bites .
- Saliva was collected from 3-15 day old adult mosquitoes by placing the proboscis of each mosquito into a capillary tube filled with water. Salivation was induced by applying 0.5 ⁇ l of 0.5% malathion in acetone to the thorax [Boorman, 1987] . One hour later, the contents of capillary tubes containing saliva were collected, pooled, and lyophilized. The saliva was reconstituted by dissolving the lyophilized proteins in 0.02 M phosphate buffered saline. In general, the protein concentration was 0.6 mg/ml for Ae .
- vexans extract 0.4 mg/ml for Cx. quinquefacia tus extract, and 0.3 mg/ml for Ae. aegypti extract as measured by a Bio- Rad Protein Assay kit (Bio-Rad Labs, Richmond, CA) .
- Skin bite tests and blood samples Skin bite tests were performed with one Ae . vexans mosquito and one Ae . aegypti mosquito on the volar aspect of each subject's forearm as previously described [Peng et al . , 1996] .
- the wheal and flare circumferences were traced at 20 minutes and 24 hours after the bite, using a felt- tipped pen. All wheal and flare tracings were transferred to transparent paper.
- the area of the wheal, flare or induration was measured using an IBM-PC (IBM Instruments, Inc., Danbury, Conn.) digitizer and stereometric measurement software [Simons, et al, 1990] .
- a wheal of less than 0.3 cm 2 with no flare and no itch was considered to be a negative immediate reaction.
- An induration less than 0.3 cm 2 was considered to be a negative delayed reaction.
- Preparation of mosquito salivary gland extract Preparation of mosquito salivary gland extract:
- Mosquitos (Aedes vexans) , collected and identified in the Department of Entomology, University of Manitoba, were anaesthetized by chilling them at 4 C C in a refrigerator.
- Salivary glands were dissected from female mosquitos in 0.02 M phosphate buffered saline (PBS) , pH 7.2 under a binocular microscope and immediately transferred to 1 ml of PBS on ice .
- a total of 370 salivary glands were gathered in 1 ml of PBS, ultrasonicated for 30 seconds, and centrifuged at 8820 g for 15 minutes. The supernatant was collected, aliquoted, and stored at -70°C.
- the protein concentration of the antigen preparation was 0.6 mg/ml as determined by the Lowry method.
- Measurement of human serum mosquito-specific IgE and IgG by ELISA Mosquito-specific IgE and IgG in human sera were measured using indirect ELISAs . Standardization of ELISA results between assays and the estimation of relative amount of mosquito-specific IgE or IgG in each sample was accomplished by using reference IgE and IgG sera. These reference sera were obtained from one subject with a high value of mosquito-specific IgE and another subject with a high value of mosquito-specific IgG and were defined as 1,000 U/ml for mosquito-specific IgE and IgG antibodies, respectively. Polystyrene immunoplates
- 0.1 ml of the enzyme substrate (1 mg/ml of p-nitrophenylphosphate in diethanolamine buffer, pH 9.8) was added and incubated overnight at 4°C. The reaction was stopped by addition of 0.1 ml of 1 N NaOH .
- Optical absorbance at 410 nm was read, using the THERMOmax microplate reader (Molecular Devices, CA,
- mosquito-specific antibodies was calculated by interpolation from the dilution curve of the reference serum.
- IgE and IgG determinations were performed on two dilutions of serum, with each dilution duplicated. 50 samples were assayed twice for mosquito-specific IgE and IgG .
- Inhibition tests In order to examine the specificity of the assays, inhibition tests were conducted [Peng et al, 1995] .
- the mosquito salivary gland extract was 10- fold sequentially diluted in ELISA buffer. Each dilution of the extract was incubated with a diluted serum with high mosquito-specific IgE or high mosquito-specific IgG for two hours at 37°C and then followed by 4°C overnight. The final serum dilution was one in 20 for the inhibition of IgE and one in 200 for that of
- SDS-PAGE and silver stain Proteins from mosquito extracts were separated by SDS-PAGE under reducing conditions in a discontinuous system using a Bio-Rad mini slab gel apparatus. One to two micrograms each of the laboratory-made mosquito whole body, head and thorax, salivary gland, and saliva extracts, were loaded onto different wells and electrophoresed in 10% acrylamide SDS-PAGE. Molecular weight protein standards (Bio-Rad) were used to determine the relative molecular weights of the electrophoresed components. Separated proteins were detected by silver staining (Bio-Rad Silver Stain kit) .
- the proteins in the mosquito extracts were separated by SDS-PAGE in a discontinuous system according to Laemmli [1970] using a Bio-Rad slab gel apparatus. For each mosquito extract, fifteen micrograms of proteins prepared in a reducing buffer were loaded onto each well and separated by electrophoresis in 12% SDS-PAGE. These proteins were then electro-transferred onto nitrocellulose membranes. Free binding sites on the membranes were blocked by incubation with 3% bovine serum albumin (Sigma, St. Louis, MO) dissolved in 0.02 M PBS for two hours.
- bovine serum albumin Sigma, St. Louis, MO
- Immunoblot was completed by incubation of the membranes with a pooled serum exhibiting high mosquito-specific IgE and IgG (1:10 dilution for IgE and 1:50 for IgG) over night . This was followed by incubation with monoclonal anti-human IgE (1:15,000) (ascites, clone No. 7.12, a gift from Dr. A. Saxon, Univ. of California) or monoclonal anti-human IgG (1:15,000) (PharMingen, CA) for 1.5 hours.
- the membranes were incubated with horseradish peroxidase conjugated goat anti-mouse IgG (1:5,000 dilution for IgE and 1:10,000 for IgG) (Calbiochem Corporation, CA) for 1.5 hours. After washing, the membranes were incubated in ECL detecting reagents (Amersham Life Science, Buckinghamshire, England)) and then exposed to Kodak film (X-Omat, Kodak) .
- PBS and umbilical cord serum were used respectively to replace the pooled human serum as controls.
- Pre-stained SDS-PAGE standards Bio-Rad, Richmond, CA were used to determine the relative molecular weights of the electrophoresed components.
- Epicutaneous tests with the seven commercial mosquito extracts and the four laboratory mosquito preparations were performed on two subjects with severe skin reactions to Aedes aegypti bites and on two subjects with no skin reaction to the bites. Histamine phosphate (1 mg/ml) , saline and 50% glycerin in saline were used as positive and negative controls, respectively.
- Mosquito bite tests were performed using female mosquitoes (Aedes aegypti ) reared in the laboratory. Skin immediate wheal and flare reactions were measured 30 minutes after the tests and skin delayed papule reactions were measured 24 hours later using the largest and the orthogonal diameters of the wheal or the papule, respectively.
- the area of the wheal or papule was calculated after subtracting the area of the wheal or papule produced by the relevant negative control (if present) .
- Protein assay Protein concentration of each commercial mosquito extract and laboratory mosquito preparations was determined by a Bio-Rad Protein Assay kit (Bio-Rad Labs, Richmond, CA) .
- SDS-PAGE and immunoblot analysis of IgE and IgG binding antigens The pooled serum used in immunoblotting was obtained from six subjects exhibiting severe skin reactions to mosquito bites and high mosquito-specific IgE and IgG as measured by ELISA. These subjects, including the two skin and bite test positive subjects, lived in Manitoba or Texas where the Aedes and/or Culex mosquito species are abundant .
- Epicutaneous tests and protein concentrations Immediate and delayed reactions were found at the sites of skin tests and mosquito bites in the two subjects allergic to mosquito bites.
- the immediate reaction was a pruritic wheal with a surrounding flare appearing within a few minutes, peaking at 30 minutes and then subsiding.
- the delayed papules were found several hours later, reaching a peak 24 hours after the epicutaneous and the bite tests. In contrast, there was little or no skin reaction to either the epicutaneous sites or the bite site in the two control subjects.
- SDS-PAGE and silver stain In the four laboratory preparations, rank ordered from whole body, head and thorax, salivary gland to saliva extracts, the amount of salivary antigens significantly increased, while non-salivary proteins and antigens significantly decreased. There were 24 visible protein bands in the head and thorax extract, 16 in the salivary gland extract, but only nine in the saliva extract. When commercial extracts containing the same amount of protein were used, the protein bands were obscure and the background was very dark. SDS-PAGE and immunoblot analysis: The IgE and IgG binding antigens in the seven commercial mosquito extracts were measured.
- the antigens of the three commercial Aedes extracts were compared to the antigens in the Aedes aegypti saliva extract, while the antigens of the four commercial Cul ex extracts were compared to the antigens in the Culex quinquefacia tus salivary gland extract.
- Culex quinquefascia tus and Culex pipiens belong to the same genus and are sibling species. Because the Cul ex species does not salivate using the method applied to induce Aedes species to salivate, the salivary gland extract of Culex quinquefaciatus was used to compare antigens with the Culex pipiens whole body extracts.
- IgE and IgG binding antigens varied greatly both in the number of antigen bands and the amount of each antigen. Multiple antigens were found in the commercial extracts. Most of these antigens were not present in the saliva or salivary gland extract. Some extracts, Cl, C2 , C3 , contained small amounts of saliva antigens. Two extracts, C5 and C7, contained no visible saliva or salivary gland antigens, although they did contain other proteins (0.09 and 1.67 mg/ml of proteins, respectively) . The IgE and IgG binding antigens in one commercial mosquito whole body extract and four laboratory-made mosquito preparations (whole body, head and thorax, salivary gland and saliva) were observed.
- the antibodies observed in the human subjects directed against these non-saliva antigens in the commercial extracts may have been induced by inhalation of insect particles or by being bitten by other insects whose antigens cross- reacted with mosquito body components leading to the formation of IgE and IgG antibodies against mosquito body antigens .
- Standardization of the extracts is required because the process of collecting or extracting mosquito saliva is extremely tedious, it is currently impractical to use mosquito saliva or salivary gland extracts in diagnosis or immunotherapy. Therefore if commercially available mosquito extracts are to be used they must be standardized to increase the quantity of the active materials they contain. Standardization of antigen preparation is usually achieved by comparison of overall activity or major components of the extract with those of a reference preparation. An in-house reference mosquito extract and a pooled serum for each mosquito genus are used to evaluate the relative biological activity and the lot-to-lot variation of different batches of mosquito extracts including species specific and non-specific components. However, this procedure is not efficient and better means of standardized extracts are required.
- the present invention provides the use of recombinant salivary allergens to be used as a "recombinant extract" to simplify the need for standardization and to provide greater safety in immunotherapy.
- mosquito saliva antigens In order to improve diagnosis and immunotherapy of mosquito allergy, purified or recombinant mosquito saliva antigens should be used as shown in Example 1. In order to do so, it should be determined if there are any cross-reactive skin and IgE responses and species- shared antigens among various mosquito species, especially those with world-wide distribution.
- Ae . vexans, Ae. aegypti , and Cx. quinquefasciatus are the three most important mosquito species distributed globally. Ae. aegypti (see generally
- Mosquitoes, mosquito saliva and salivary gland extracts Female Ae . vexans mosquitoes were collected in local fields and identified by scientists in the Department of Entomology, University of Manitoba. The Ae . aegypti colony was obtained from the same
- the Cx. quinquefaciatus colony was imported from Dr. Robert J. Novak's laboratory, University of Illinois, Champaign, IL, and maintained in our laboratory.
- Four to twelve day old adult Ae . aegypti mosquitos were used for the bite tests and for saliva collection.
- Salivary glands were dissected from four to twelve day old adult Cx. quinquefaciatus mosquitoes.
- Mosquito saliva or salivary gland extracts were prepared for use in the ELISA and immunoblot as described herein above.
- ELISA Serum mosquito-specific IgE to Ae . vexans, Ae . aegypti , and Cx. quinquefaciatus were measured by an indirect ELISA as described herein above. Optimal conditions for dilutions of the 3 mosquito extracts, serum samples, goat anti-human IgE, and conjugated rabbit anti-goat IgG were chosen by checkerboard titration. Standardization of ELISA results between assays and estimation of the relative amount of mosquito-specific IgE in each sample was accomplished by using reference sera as described. The reference serum used to measure Ae . aegypti- IgE and Cx.
- quinquefaciatus- IgE was obtained from a subject with systemic reactions to mosquito bites (kindly provided by Dr. R.J. Engler, Walter Reed Army Medical Centre, Washington, D.C.) .
- Another reference serum used to measure Ae . vexans- IgE came from a Manitoban with severe skin reactions to mosquito bites (immediate wheal 1.5 cm 2 and flare 11.6 cm 2 ) . Both reference sera were defined as 1000 U/ml for mosquito-specific IgE.
- Microplates coated with mosquito saliva or salivary gland extract were sequentially incubated with serum samples (1:20) or reference serum (2-fold dilutions from 1:20 to 1:10,240), 1:1,000 goat anti-human IgE (P.S. myeloma-affinity purified, a gift from Dr. N.F. Adkinson, Jr., The Johns Hopkins Allergy and Asthma Centre), 1:1,000 alkaline phosphatase- conjugated rabbit anti-goat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) .
- the values of mosquito- specific IgE in the tested samples were calculated by interpolation from the dilution curve of the reference serum.
- the sensitivity of the ELISAs was 0.8 U/ml.
- ELISA inhibition tests In order to study the cross- reactivity among the three species, ELISA inhibition tests were performed. A serum with high mosquito- specific IgE (final dilution 1:20) was incubated with serially diluted Ae. vexans, Ae aegypti , Cx. quinquefaciatus extracts with final dilutions of 1:4 and 1:20 at room temperature for one hour and then 4°C overnight. Incubation of the serum with ELISA buffer served as a positive control. These incubated materials were then measured for Ae. aegypti-IgE using ELISA.
- SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
- Proteins separated by SDS-PAGE were electrophoretically transferred onto nitrocellulose membranes. Free binding sites on the membranes were blocked by incubation for two hours with 3% bovine serum albumin in 0.02 M phosphate buffered saline, pH 7.4, containing 0.05% (v/v) Tween 20 (PBS- T) . After washing three times with PBS-T, the membranes were incubated overnight with the pooled serum (1:10 dilution for IgE and 1:50 for IgG) and washed again. Incubation of the membranes with PBS-T served as a negative control. This was followed by sequential incubations with 1:15,000 monoclonal anti- human IgE (clone 7.12, from Dr. A. Saxon's laboratory, University of California) or 1:15,000 monoclonal anti- human IgG (PharMingen, San Diego, CA) , and then HRP- conjugated goat anti-mouse IgG (1:5,000 for IgE,
- Mosquito-specific IgE levels The geometric mean Ae. vexans- IgE, Ae. aegypti-IgE, and Cx. quinquefaciatus- IgE were all significantly higher in the subjects with immediate skin reactions to Ae. vexans bites than in those with no immediate skin reaction to the bites (p's ⁇ 0.05) . Similar results were found for mean mosquito- specific IgE levels of the three species in the subjects with or without immediate skin reactions to Ae. aegypti bites ( Figure 2 bottom) . Significant correlations were also found among the IgE levels of the three species (r's between 0.35 to 0.60, p's ⁇ 0.03) .
- vexans bites e.g. aegypti-specific IgE reactions could be inhibited by incubation of the serum with all three extracts in a dose-dependent manner, confirming the existence of species-shared antigens among the extracts of the three species.
- SDS-PAGE and immunoblot analysis Immunoblot analysis further revealed the existence of species-shared antigens. Using the pooled serum from Manitobans allergic to mosquitos, the IgE and IgG antibodies not only bound to Ae . vexans antigens, but also to the antigens of the two species which are not found in Manitoba.
- the immunologic basis for the reactive skin and IgE responses among different mosquito species is the existence of species-shared antigens which are based on their identical protein sequences. Salivary secretions have been demonstrated to be directly responsible for skin reactions to mosquito bites. In the present Example, immunoblot analysis using saliva or salivary gland extracts, a number of species-shared antigens and several Ae. vexans-specific antigens were found.
- Reactions to mosquito bites are generally caused by immunologic mechanisms, with both type I (IgE- mediated) and type IV (cell-mediated) hypersensitivities being involved [Oka K, 1989; Peng et al, 1996; Reunala et al, 1994a; 1994b] .
- Serum mosquito- specific IgE has been demonstrated to correlate with cutaneous mosquito bite reactions [Oka K, 1989; Peng et al, 1996] .
- Mosquito-specific IgG has also been found to correlate with skin mosquito bite reactions, suggesting that IgG may also be involved in the development of mosquito allergy [Peng et al, 1996] .
- Mosquito antigens have been identified by immunoblot analysis. A number of mosquito antigens with molecular masses ranging from 14 to 126 kDa have been reported in various mosquito species [Penneys et al, 1989; Shen et al . , 1989; Wu and Lan, 1989; Brummer-
- antigens are analyzed using immunoblot techniques on three mosquito species not previously examined; Aedes (Ae . ) vexans, a globally distributed species (and the major pest species in Manitoba) , and two North American species Culex (Cx. ) tar sal is and Culiseta (Cs . ) inornata .
- Subjects This study was approved by The University of Manitoba Faculty Committee on the Use of Human Subjects in Research, and the subjects gave written, informed consent before participation. Forty-two subjects with a history of local reactions to mosquito bites were recruited during the summer of 1993. Skin mosquito Ae . vexans bite tests were performed and serum mosquito (Ae .
- salivary gland-specific IgE and IgG antibodies salivary gland-specific IgE and IgG antibodies (mosquito-specific IgE and IgG) were measured by ELISA in 42 subjects.
- Skin reactions in the bite tests and antibody levels in the five subjects studied are listed in Table 3.
- the reactive subjects had very strong skin immediate reactions which consisted of a pruritic wheal (> 1 cm) with surrounding flare appearing within several minutes, reaching a peak at 30 minutes and then subsiding.
- the immediate reaction was followed by a local pruritic and indurated papule and erythema ( ⁇ 7 cm) which appeared several hours later, reaching a peak 24 hours after the bite.
- the papule usually lasted several days.
- a pooled serum from reactive subjects was used in the analysis of antigens in the three mosquito species .
- Mosquito head and thorax extracts Extracts prepared from mosquito heads and thoraxes were used in the study.
- Female mosquitoes of the three species (Ae . vexans, Cx. tarsalis , Cs . inornata) were collected and identified by the Insect Control Branch, Parks and Adventure Department, City of Winnipeg, and then stored at -70°C.
- the heads and thoraxes were placed in cold 0.02 M phosphate buffered saline (PBS), pH 7.2, homogenized on ice for 1 minute using a PCU 11 homogenizer (Kinematica, Switzerland) , centrifuged at 8820 g for 30 minutes, filtered through a 0.45 ⁇ m Amicon filter, and then stored at -70°C.
- the protein concentrations of the antigen preparations were 1.48 mg/ml for Ae . vexans , 6.13 mg/ml for Cx. tarsalis and 5.34 mg/ml for Cs . inornata , as measured by the Protein Assay Dye Reagent kit (Bio-Rad Laboratories, Richmond,
- Inhibition test To examine the specificity of the immunoblot analysis, an antigen inhibition test was performed. Prior to immunoblotting, the pooled serum with high mosquito-specific IgE and IgG was incubated with Ae . vexans head and thorax extract with a final dilution of 1:2, 1:20 or 1:200 at 4°C overnight. Incubation of the serum with PBS served as a positive control. SDS-PAGE and immunoblotting for IgE and IgG binding antigens was then performed with these pre- incubated serum samples. After incubation with mosquito extract, both IgE and IgG binding bands were significantly reduced compared to the positive control.
- IgE and IgG binding antigens are specific to mosquito antigens.
- Antigens in the three mosquito species IgE and IgG antibodies bound to various mosquito antigens in the three species. Twelve antigens in Ae . vexans, 16 antigens in Cx. tarsalis, and 14 antigens in Cs . inornata , with molecular masses ranging from 18.5 to 160 kDa, were found by immunoblot analysis (Table 4) . Most of the antigens bound to both IgE and IgG, and were shared by species.
- Figure 3 shows the IgE (left) and IgG (right) responses to the antigens of Ae .
- vexans in three subjects with severe skin reactions to the bites (strip #1-3) and two subjects without skin reactions to the bites (strips #4 and #5) .
- the patterns (spectra) of IgE and IgG responses to the antigens were similar, but the magnitudes of the antibody responses varied suggestively.
- extracts of one globally distributed mosquito species (Aedes vexans) and two North American species ( Culex tarsalis and Culiseta inornata) were prepared from heads and thoraxes . Proteins of the three extracts were separated by 12% SDS-PAGE and transferred to nitrocellulose membranes for immunoblotting.
- Immunoblotting was completed by sequential incubations of the membranes with a pooled human serum from subjects allergic to mosquito bites, monoclonal antibodies to human IgE or IgG, and goat anti-mouse IgG conjugate. Twelve to sixteen antigens with molecular masses ranging from 18.5 to 160 kDa were found in each extract. Nine antigens were shared by three species and six were shared by two species. Only three were species-unique. Most antigens bound to both IgE and IgG antibodies.
- IgE and IgG antibodies against Aedes vexans were studied by immunoblotting using individual serum from subjects with or without skin reactions to Aedes vexans bites. All three subjects with severe skin reactions had strong IgE and IgG antibodies to 32.5, 40, and 50 kDa proteins . The patterns and magnitudes of IgE and IgG antibodies to the antigens varied among individuals. Very faint IgE antibodies to these antigens were found in the 2 subjects with no skin reactions, suggesting that IgE plays a role in the development of mosquito allergy.
- clones were grouped into A, B and C, according to the color strength of their reactions to the mouse antiserum on the filters.
- Four clones from each group were chosen to prepare fusion proteins using the method previously described [Huynh et al . , 1985]. Twelve samples of the fusion protein were separated by SDS-PAGE and immunoblotted by mouse anti- saliva serum. A protein band with a molecular weight ranging from 125 to 175 kDa was found in each sample (data not shown) .
- the ⁇ -galactosidase part of the fusion protein is 114 kDa
- the cDNA coding part ranged from 10 to 60 kDa.
- PCR was designed to clone the 5 ' terminal fragment from the cDNA library using the lambda gtll forward primer (5' GACTCCTGGAGCCCG 3', Clontech; SEQ ID No: 2) and a synthesized 3' primer (3 ' ATATCTGTCCACCAACG 5 ' ; SEQ ID No: 3) complementary to a sequence of the 3' terminal fragment.
- PCR was performed in 100 ⁇ l of the sample containing 0.5 ⁇ g of library DNA, 10 ⁇ l of lOx buffer, 2 ⁇ l of 25 M dNTP's, 2 ⁇ l of 100 ng/ ⁇ l each primer, 2 U of Taq polymerase supplied by the PCR kit (Boehringer Mannheim Canada, Quebec) .
- the reaction was subjected to 25 cycles of amplification consisting of 1 minute at 94°C, one minute at 55°C and one minute at 72°C, with a final 72°C extension for seven minutes.
- the PCR product was cloned into the TA vector (Invitrogen, San Diego, CA, USA) .
- PCR clones Three PCR clones were obtained and sequenced. The sequences of the three clones were found to be identical and overlapped AA22 cDNA. In the search for an initiation codon in the same open reading frame as AA22 cDNA, an ATG was found, which was characterized with an adenosine at the crucial -3 position of the Kozak consensus sequence, A/GXXXATG, for initiation of translation by eukaryotic ribosomes [Kozak, 1987] . The sequence flanking the putative translational start sites, GAAAATG, is very similar to the consensus sequence, C/AAAA/CATG, for initiation of Drosophila , an insect gene (Cavener, 1987] . The full-length cDNA is 0.85 kb, coding for a protein of 253 amino acid residues, approximately 30 kDa.
- the fusion protein- selected human IgE strongly bound to the 30 kDa native protein (lane 2) , suggesting that the cDNA isolated codes the 30 kDa salivary allergen which induces a specific IgE response in mosquito-allergic humans.
- This IgE-binding protein is the third salivary allergen of Aedes aegypti whose cDNA has been cloned and sequenced.
- the protein is rich in glutamic acid residues (16.5% of amino acid residues), and has a hydrophobic amino terminal region characteristic of a secretory signal peptide [Hopp et al . , 1981; Kyte et al . , 1982].
- Aed a 1 a 68 kDa mosquito Aedes aegypti salivary protein, is an allergen which binds to the IgE of mosquito-allergic subjects.
- an expressed, purified recombinant Aed a 1 (rAed a 1) was characterized to determine if it bound to antibodies directed to the native protein. Additionally, responses to it in mosquito-allergic subjects was investigated to determine its biologic activity, that is activity in vivo to elicit an immune response .
- Two cDNA segments were ligated together forming the full-length Aed a 1 gene, which was inserted into the baculovirus expression vector pBlueBacHis C.
- Recombinant baculoviruses were generated by co- infection of Sf9 insect cells with wild-type baculovirus AcMNPV DNA and the recombinant vector.
- Western blot using rabbit anti-rAed a 1 the resultant baculovirus were proved to express the 68 kDa rAed a 1 which was secreted into the culture medium as a non- fusion protein.
- the recombinant Aed a 1 showed identical immunological reaction with the native Aed a 1 in the saliva.
- rAed a 1 in the culture medium was then purified using anion exchange and gel filtration chromatography.
- This Example demonstrates that the recombinant Aed a 1 expressed by the baculovirus system has the same antigenicity and biological activity as the native Aed a 1 present in mosquito saliva and is a major salivary allergen of Ae. aegypti .
- Mosquito salivary proteins cause allergic reactions in humans .
- Aed a 2 a 37 kDa mosquito Aedes aegypti salivary protein, is an allergen which binds to the IgE of mosquito-allergic subjects.
- an expressed, purified recombinant Aed a 2 (rAed a 2) , was characterized to determine if it bound to antibodies directed to the native protein. Additionally, responses to it in mosquito-allergic subjects was investigated to determine its biologic activity, that is activity in vivo to elicit an immune response.
- Sf9 insect cells were co-infected with the transfer vector pVL1392/Aed a 2 DNA and wild-type baculovirus.
- the transfer vector pVL1392/Aed a 2 DNA and wild-type baculovirus.
- the transfer vector pVL1392/Aed a 2 was proved to express rAed a 2, which was secreted into the culture medium as a non-fusion protein.
- the optimal expression of rAed a 2 occurred at 96 hours after infection.
- rAed a 2 was then purified from the culture medium to homogeneity using anion-exchange (DEAE Sephacel) chromatography.
- DEAE Sephacel anion-exchange
- the rAed 2 was able to bindT ⁇ to the IgE of mosquito-allergic sera in Western blot and ELISA. This binding was inhibited by addition of mosquito head and thorax extract in a dose-dependent manner, showing that the binding of mosquito antigens to human IgE is specific ( Figure 7) .
- Skin (epicutaneous) tests with purified rAed a 2 and a commercial crude Ae. aegypti extract were performed in 31 subjects with positive reactions in Ae . aegypti bite tests and 17 subjects with negative reactions in the bite tests. Immediate wheals and flares were measured 20 minutes after the testing, and delayed reactions were measured 24 hours later.
- Aed a 2 was also shown to be a species-shared allergen, being present in the saliva or salivary gland extracts of 6 Aedes and one Culex species among the 12 species studied ( Figure 8) .
- Aed a 2 expressed by the baculovirus system has identical antigenicity and biological activity with native Aed a 2 present in mosquito saliva and that Aed a 2 is a common allergen shared by Aedes genus and other species.
- saliva or salivary gland extracts were prepared as described herein above from ten mosquito species including seven species with worldwide distribution. These species are Ae . aegypti , Ae . vexans, Ae . albopictus , Ae . togoi , Ae . triseria tus, Cx. quinquefasciatus, Cx. pipiens, Cx. tarsalis, An . sinensis and Cs . inornata . Proteins from the mosquito preparations were separated by SDS-PAGE and then transferred to nitrocellulose membranes.
- the membranes were immunoblotted by sequential incubations of the membranes with human serum, monoclonal anti-human IgE, and enzyme-conjugated goat anti-mouse IgG.
- Salivary allergens were analyzed using a pooled serum from mosquito-allergic subjects.
- a 37 to 39 kDa protein 9/25826 recognized by rabbit anti-Aed a 2 was identified in all 3 Aedes species studied (Fig. 10B strips #1 - #3) , and in Cx. quinquefasciatus as well (Fig. 10B strip #4) .
- Salivary allergens elicited higher IgE responses in mosquito-allergic subjects than in non-allergic subjects.
- Three major Aedes species (Ae . aegypti , Ae . vexans, Ae . albopictus) had a higher number of allergens which also elicited stronger IgE responses, suggesting that they are major biting species.
- the saliva injected may cause a variety of local and systemic adverse reactions, for which young children are at high risk.
- GGC AAA GAG GAG AAT ACA GGA CAT GAG GAT GCT GGT GAG GAA 251 G K E E N T G H E D A G E E
- the clone was sequenced several times in both directions by the Sanger (1977) method using a US Biochemicals sequence kit.
- the putative secretory signal peptide is underlined.
- a translation initiation codon (ATG) and consensus polyadenylation signal sequence (AATAAA) are shown in bold.
- the sequence data have been deposited in the GenBank databases under accession No. AF001927.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002309387A CA2309387A1 (en) | 1997-11-13 | 1998-11-13 | Method and kit for determining severe inflammatory reactions to mosquito bites |
AU12560/99A AU1256099A (en) | 1997-11-13 | 1998-11-13 | Method and kit for determining severe inflammatory reactions to mosquito bites |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6540297P | 1997-11-13 | 1997-11-13 | |
US60/065,402 | 1997-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999025826A1 true WO1999025826A1 (en) | 1999-05-27 |
Family
ID=22062462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1998/001961 WO1999025826A1 (en) | 1997-11-13 | 1998-11-13 | Method and kit for determining severe inflammatory reactions to mosquito bites |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1256099A (en) |
CA (1) | CA2309387A1 (en) |
WO (1) | WO1999025826A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021800A1 (en) * | 1999-09-20 | 2001-03-29 | Aberdeen University | Monoclonal antibody 3f1h10 neutralising vhsv (viral haemorrhagic septicaemia virus) |
US20050101031A1 (en) * | 2000-10-03 | 2005-05-12 | Reinhard Hiller | Allergen-microarray assay |
EP1935347A1 (en) * | 2006-12-21 | 2008-06-25 | Bayer Healthcare, LLC | Method of analyzing for at least one allergy |
WO2009009493A2 (en) * | 2007-07-09 | 2009-01-15 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Aegyptin and uses thereof |
WO2017027677A1 (en) * | 2015-08-11 | 2017-02-16 | University Of Central Florida Research Foundation, Inc. | Passive insect surveillance sensor device |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004274A1 (en) * | 1996-07-31 | 1998-02-05 | University Of Manitoba | Recombinant mosquito salivary allergens |
-
1998
- 1998-11-13 CA CA002309387A patent/CA2309387A1/en not_active Abandoned
- 1998-11-13 WO PCT/IB1998/001961 patent/WO1999025826A1/en active Application Filing
- 1998-11-13 AU AU12560/99A patent/AU1256099A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004274A1 (en) * | 1996-07-31 | 1998-02-05 | University Of Manitoba | Recombinant mosquito salivary allergens |
Non-Patent Citations (4)
Title |
---|
PENG Z. ET AL: "Cross-reactivity of skin and serum specific IgE responses and allergen analysis for three mosquito species with worldwide distribution.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1997) 100/2 (192-198). REFS: 36 ISSN: 0091-6749 CODEN: JACIBY, XP002098985 * |
XU W ET AL.: "Molecular cloning and characterization of the gene encoding a 30 kDa salivary allergen of mosquito Aedes aegypti (accession number AF001927).", EMBL SEQUENCE DATABASE, 26 May 1997 (1997-05-26), Heidelberg, Germany, XP002098988 * |
XU, W. ET AL: "Mosquito allergy: Expression, purification, and characterization of Aed a 2, an Aedes (Ae.) aegypti salivary allergen.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1997) VOL. 99, NO. 1 PART 2, PP. S152. MEETING INFO.: JOINT MEETING OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE CLINICAL IMMUNOLOGY SOCIETY, XP002098987 * |
YANG J ET AL.: "Production and identification of monoclonal antibodies to mosquito [Aedes (Ae.) aegypti] salivary allergens", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1997) VOL. 99, NO. 1 PART 2, PP. S152. MEETING INFO.: JOINT MEETING OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE CLINICAL IMMUNOLOGY SOCIETY, XP002098986 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021800A1 (en) * | 1999-09-20 | 2001-03-29 | Aberdeen University | Monoclonal antibody 3f1h10 neutralising vhsv (viral haemorrhagic septicaemia virus) |
US7265095B1 (en) | 1999-09-20 | 2007-09-04 | Aberdeen University | Monoclonal antibody 3F1H10 neutralising VHSV (viral haemorrhagic septicaemia virus) |
US20050101031A1 (en) * | 2000-10-03 | 2005-05-12 | Reinhard Hiller | Allergen-microarray assay |
US20080139406A1 (en) * | 2000-10-03 | 2008-06-12 | Reinhard Hiller | Allergen-Microarray Assay |
EP1935347A1 (en) * | 2006-12-21 | 2008-06-25 | Bayer Healthcare, LLC | Method of analyzing for at least one allergy |
EP2335598A1 (en) * | 2006-12-21 | 2011-06-22 | Bayer Healthcare LLC | Method of analyzing for at least one allergy |
WO2009009493A3 (en) * | 2007-07-09 | 2009-02-26 | Us Gov Health & Human Serv | Aegyptin and uses thereof |
WO2009009493A2 (en) * | 2007-07-09 | 2009-01-15 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Aegyptin and uses thereof |
US8383589B2 (en) | 2007-07-09 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aegyptin and uses thereof |
US8980859B2 (en) | 2007-07-09 | 2015-03-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Aegyptin and uses thereof |
US9441022B2 (en) | 2007-07-09 | 2016-09-13 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Aegyptin and uses thereof |
WO2017027677A1 (en) * | 2015-08-11 | 2017-02-16 | University Of Central Florida Research Foundation, Inc. | Passive insect surveillance sensor device |
US10948491B2 (en) | 2015-08-11 | 2021-03-16 | University Of Central Florida Research Foundation, Inc. | Passive insect surveillance sensor device |
US11693004B2 (en) | 2015-08-11 | 2023-07-04 | University Of Central Florida Research Foundation, Inc. | Passive insect surveillance sensor device |
Also Published As
Publication number | Publication date |
---|---|
CA2309387A1 (en) | 1999-05-27 |
AU1256099A (en) | 1999-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hilger et al. | IgE-mediated anaphylaxis caused by bites of the pigeon tick Argas reflexus: cloning and expression of the major allergen Arg r 1 | |
Peng et al. | Production and characterization of monoclonal antibodies to two new mosquito Aedes aegypti salivary proteins | |
US8003382B2 (en) | Nucleic acid molecules encoding a house dust mite allergen Der f VII, and antigenic peptides thereof | |
EP0445135A1 (en) | Immogenically active fractions of borrelia burgdorferi. | |
Beezhold et al. | Human IgE-binding epitopes of the latex allergen Hev b 5 | |
JP2007006896A (en) | Ryegrass pollen allergen | |
EP0665888B1 (en) | Ryegrass pollen allergen | |
Pajarón et al. | Cross‐reactivity of Olea europaea with other Oleaceae species in allergic rhinitis and bronchial asthma | |
EP0463059B1 (en) | Allergenic proteins from ragweed and uses therefor | |
JPH0797395A (en) | Peptides containing sequence of porphyromonas gingivalis cilium protein and its use | |
Tang et al. | Antibody binding of deletion mutants of Asp f 2, the major Aspergillus fumigatus allergen | |
WO1999025826A1 (en) | Method and kit for determining severe inflammatory reactions to mosquito bites | |
KR100465382B1 (en) | Antigenic protein originating in malassezia | |
El Ridi et al. | T and B cell reactivity to a 42-kDa protein is associated with human resistance to both schistosomiasis mansoni and haematobium | |
KR100455023B1 (en) | T-cell Epitope of Taraxacum Pollen Allergens | |
WO1998004274A1 (en) | Recombinant mosquito salivary allergens | |
WO1998004274A9 (en) | Recombinant mosquito salivary allergens | |
WO1996032479A1 (en) | Hookworm vaccine | |
US5698204A (en) | Recombinant allergenic proteins from ragweed pollen | |
JPH11503609A (en) | Novel proteins from canine filamentous worms and immunodiagnostic methods for canine filamentous worms in mammals | |
US5578453A (en) | Cloning and expression of toxoplasma antigens and use of recombinant antigens | |
CA2154379A1 (en) | Parietaria allergens | |
US5344645A (en) | Immunogens derived from pathogen-free tick species or cell lines, and tick vaccines derived therefrom | |
Heymann et al. | Recent progress in mite allergen immunochemistry | |
JP3588615B2 (en) | Recombinant mite allergen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2309387 Country of ref document: CA Ref country code: CA Ref document number: 2309387 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09554446 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |